Provided by Tiger Trade Technology Pte. Ltd.

Oramed Pharmaceuticals

3.43
+0.02000.59%
Pre-market: 3.34-0.0900-2.62%04:56 EST
Volume:164.32K
Turnover:565.66K
Market Cap:136.52M
PE:3.34
High:3.49
Open:3.40
Low:3.36
Close:3.41
52wk High:3.71
52wk Low:1.82
Shares:39.80M
Float Shares:32.56M
Volume Ratio:0.97
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.03
EPS(LYR):-0.4800
ROE:24.48%
ROA:-4.22%
PB:0.67
PE(LYR):-7.15

Loading ...

Oramed Transfers Oral Drug Platform to Lifeward in Strategic Deal

Reuters
·
Jan 15

Lifeward Ltd - Receives up to $47 Mln Investment From Oramed and Another Investor

THOMSON REUTERS
·
Jan 13

Lifeward Ltd - Oramed to Buy up to 49.99% Equity in Lifeward

THOMSON REUTERS
·
Jan 13

Lifeward Enters Transformative Strategic Investment and Partnership Agreement With Oramed to Create a Diversified Biomedical Innovation Company

THOMSON REUTERS
·
Jan 13

Lifeward Ltd - Buys Oramed's Pod Technology for Biotech Market

THOMSON REUTERS
·
Jan 13

BRIEF-Oramed And Lifeward Announce Strategic Transaction

Reuters
·
Jan 13

Oramed Invests $9 Million in Lifeward and Transfers Oral Drug Delivery Technology

Reuters
·
Jan 13

Oramed Pharmaceuticals Inc - Lifeward to Issue $10 Mln Convertible Notes

THOMSON REUTERS
·
Jan 13

Oramed Pharmaceuticals Inc - Will Receive 4% on Net Sales of Rewalk Franchise for up to 10 Years

THOMSON REUTERS
·
Jan 13

Oramed Pharmaceuticals Inc - Mark Grant to Lead Combined Platforms

THOMSON REUTERS
·
Jan 13

Oramed Pharmaceuticals Inc - to Receive 49.9% Ownership in Lifeward

THOMSON REUTERS
·
Jan 13

Oramed and Lifeward Announce Strategic Transaction

THOMSON REUTERS
·
Jan 13

Oramed Pharmaceuticals Inc. announces $0.25 per share dividend totaling approximately $10.5 million

Reuters
·
Jan 07

Oramed Pharmaceuticals Inc: Also Maintains Its Warrant Position as Well as a Nine-Year Royalty Interest in Scilex Products

THOMSON REUTERS
·
Jan 07

Oramed Pharmaceuticals Inc - Retains $27 Mln Note and $12 Mln Convertible Note

THOMSON REUTERS
·
Jan 07

Press Release: Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments

Dow Jones
·
Jan 07

Oramed Pharmaceuticals Director Leonard Sank Resigns After 18 Years

Reuters
·
Jan 01

Scilex Completes $27 Million Repurchase of Oramed Penny Warrants

Reuters
·
Dec 31, 2025

Oramed Pharmaceuticals' (NASDAQ:ORMP) Profits May Be Overstating Its True Earnings Potential

Simply Wall St.
·
Nov 21, 2025

BRIEF-Oramed Reports Fiscal Third Quarter 2025 Financial Results

Reuters
·
Nov 17, 2025